Intra-Individual Variability of Direct Oral Anticoagulant Levels in Frail Older Patients upon, during, and after Acute Hospitalization: the DOAC-FRAIL Study.

Autor: de Jong MJ; Thrombosis Expert Center Maastricht, Department of Internal Medicine, Section of Vascular Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands. Electronic address: Melanie.de.jong@mumc.nl., Saadan H; Division of General Medicine, Department of Internal Medicine, Section of Geriatric Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands., van der Hooft BHM; Division of General Medicine, Department of Internal Medicine, Section of Geriatric Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands., Hellenbrand DLS; Department of Clinical Chemistry, Maastricht University Medical Center+, Maastricht, the Netherlands., Brüggemann RAG; Division of General Medicine, Department of Internal Medicine, Section of Geriatric Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands., Ten Cate H; Thrombosis Expert Center Maastricht, Department of Internal Medicine, Section of Vascular Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; Division of General Medicine, Department of Internal Medicine, Section of Vascular Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, the Netherlands., van Kuijk SMJ; Department of Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University, Maastricht, the Netherlands., van Geel RMJM; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, the Netherlands., Henskens YMC; Department of Clinical Chemistry, Maastricht University Medical Center+, Maastricht, the Netherlands., Winckers K; Division of General Medicine, Department of Internal Medicine, Section of Vascular Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, the Netherlands., Magdelijns FJH; Division of General Medicine, Department of Internal Medicine, Section of Geriatric Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, the Netherlands.

Publikováno v: Journal of the American Medical Directors Association [J Am Med Dir Assoc] 2024 Sep 27; Vol. 25 (12), pp. 105280. Date of Electronic Publication: 2024 Sep 27.

Systematic Evaluation of Osimertinib Population Pharmacokinetic Models in a Cohort of Dutch Adults with Non-Small Cell Lung Cancer.

Autor: Westra N; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Kruithof PD; Department of Clinical Pharmacy and Toxicology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands., Croes S; Department of Clinical Pharmacy and Toxicology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands., van Geel RMJM; Department of Clinical Pharmacy and Toxicology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands., Hendriks LEL; Department of Pulmonary Diseases, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands., Touw DJ; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.; Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands., Oude Munnink TH; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Mian P; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. p.mian@umcg.nl.

Publikováno v: European journal of drug metabolism and pharmacokinetics [Eur J Drug Metab Pharmacokinet] 2024 Jul; Vol. 49 (4), pp. 517-526. Date of Electronic Publication: 2024 Jun 15.

Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.

Autor: van Veelen A; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, Maastricht, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands., Veerman GDM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Verschueren MV; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.; Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands., Gulikers JL; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, Maastricht, The Netherlands., Steendam CMJ; Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.; Department of Pulmonary Diseases, Catharina Hospital, Eindhoven, The Netherlands., Brouns AJWM; Department of Respiratory Medicine, Zuyderland, Geleen, The Netherlands.; Department of Pulmonary Diseases, GROW-School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands., Dursun S; Department of Pulmonary Diseases, GROW-School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands., Paats MS; Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center+, Maastricht, The Netherlands., van der Leest C; Department of Pulmonology, Amphia Hospital, Breda, The Netherlands., Dingemans AC; Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van de Garde EMW; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.; Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands., Souverein P; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands., Driessen JHM; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, Maastricht, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.; NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, The Netherlands., Hendriks LEL; Department of Pulmonary Diseases, GROW-School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands., van Geel RMJM; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, Maastricht, The Netherlands., Croes S; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, Maastricht, The Netherlands.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Jan 15; Vol. 154 (2), pp. 332-342. Date of Electronic Publication: 2023 Oct 15.

Comparison of characteristics of patients with lung cancer in U.K. primary care databases: Clinical Practice Research Datalink Aurum and GOLD.

Autor: Gulikers JL; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, The Netherlands., van Veelen AJ; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Driessen JHM; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.; NUTRIM, Maastricht University Medical Centre+, Maastricht, The Netherlands., Souverein PC; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Tjan-Heijnen VCG; Division Medical Oncology, GROW, Maastricht University Medical Centre+, Maastricht, The Netherlands., Hendriks LEL; Department of Pulmonary Diseases, GROW, Maastricht University Medical Centre+, Maastricht, The Netherlands., van Geel RMJM; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, The Netherlands., Croes S; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, The Netherlands.

Publikováno v: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2023 Oct; Vol. 32 (10), pp. 1161-1177. Date of Electronic Publication: 2023 May 22.

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.

Autor: Ter Heine R; Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Geert Grooteplein Zuid 10, 6525GA, Nijmegen, The Netherlands. r.terheine@radboudumc.nl., van den Heuvel MM; Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands., Piet B; Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands., Deenen MJ; Department of Clinical Pharmacy, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands., van der Wekken AJ; Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Hendriks LEL; Department of Pulmonary Diseases, GROW-School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands., Croes S; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, Maastricht, The Netherlands., van Geel RMJM; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, The Netherlands.; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, Maastricht, The Netherlands., Jansman FGA; Department of Clinical Pharmacy, Deventer Hospital, Deventer, The Netherlands.; Unit of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands., Boshuizen RC; Department of Pulmonology, Deventer Hospital, Deventer, The Netherlands., Franssen EJF; Department of Clinical Pharmacy, Onze Lieve Vrouwe Gasthuis Hospital AC, Amsterdam, The Netherlands., Smit AAJ; Department of Pulmonology, Onze Lieve Vrouwe Gasthuis Hospital AC, Amsterdam, The Netherlands., Dumoulin DW; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Oude Munnink TH; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Smit EF; Department of Pulmonology, Leiden University Medical Centre, Leiden, The Netherlands., Derijks HJ; Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Geert Grooteplein Zuid 10, 6525GA, Nijmegen, The Netherlands.; Department of Pharmacy, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., van der Leest CH; Department of Pulmonology, Amphia Hospital, Breda, The Netherlands., Hendrikx JJMA; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute (NKI-AVL), Amsterdam, The Netherlands., Moes DJAR; Department of Clinical Pharmacology and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., de Rouw N; Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Geert Grooteplein Zuid 10, 6525GA, Nijmegen, The Netherlands.; Department of Clinical Pharmacy, Amphia Hospital, Breda, The Netherlands.

Publikováno v: Targeted oncology [Target Oncol] 2023 May; Vol. 18 (3), pp. 441-450. Date of Electronic Publication: 2023 Apr 21.